Advertisement
News
Advertisement

Meningococcal Vaccine Market Expected To Hit $3.76B By 2019

Fri, 05/09/2014 - 9:34am

According to a new report published by Transparency Market Research "Meningococcal Vaccines Market (Polysaccharide, Conjugate, and Combination Vaccines, along with Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the market for meningococcal vaccines was valued at USD 1.5 billion in 2012 and is expected to reach a value of USD 3.7 billion in 2019, growing at a CAGR of 14.9% from 2013 to 2019.

The global market for meningococcal vaccines is segmented broadly into vaccine types namely, polysaccharide, conjugate and combination vaccines. The report also provides analysis for vaccines under development that are expected to be commercialized during the forecast period 2013 to 2019. The vaccine types are further segmented by different brands available in the market. The conjugate vaccines segment is likely to lead the overall meningococcal vaccines market in terms of revenue, which is estimated to reach approximately USD 2.5 billion by 2019 at a CAGR of 12.9%. Amongst the pipeline vaccines, Novartis's Bexsero is expected to grow at the fastest rate of 24.7% during the forecast period 2013 to 2019. According to Department of Health, U.K., Bexsero is the first serogroup B vaccine to be incorporated into the national immunization program and is expected to be available in the market for sales by the second quarter of 2014. The MnB rLP2086 vaccine from Pfizer is currently in phase III clinical trials and has been granted with Breakthrough Therapy status by U.S. FDA in 2014.

Geographically, North America lead the global meningococcal vaccines market in 2012 due to government interventions, wider immunization programs, and favorable research and development initiative by manufacturers. According to National Meningitis Association of the U.S., about 20 percent of all meningococcal disease cases occur in teens and young adults aged 14 years to 24 years. As per the Centers for Disease Control and Prevention (CDC) 1,000 to 2,600 people contract meningitis annually in the U.S. Meningococcal vaccines licensed in the U.S. are only against A, C, Y and W-135 serogroups and not against serogroup B. The use of Bexsero as an Investigational New Drug (IND) in combating the disease during the outbreaks in Princeton University and University of California, Santa Barbara in 2013, is likely to clear the way for Bexsero's approval in the U.S. market sooner than expected. This region is followed by Rest of the World comprising the Latin American countries, the Middle East and African countries. This has been attributed to the high incidence rate of meningococcal diseases in this region. Europe accounts for the lowest CAGR due to rise free sales of the vaccines especially meningococcal C vaccines.

By 2019, Asia-Pacific is estimated to be the fastest growing regional market with a CAGR of around 17.1%. Major drivers for this market include low cost of manufacturing and transfer of novel technologies with respect to vaccine manufacturing, from developed parts of the world to the emerging economies. Advancements in manufacturing technology have been helping companies in manufacturing novel products that are not only affordable in developing and underprivileged nations, but are also comparable in terms of quality to their high-end alternatives.

The global market for meningococcal vaccines is largely driven by increasing government intervention in reforming the healthcare infrastructure and incorporation of legislations specific to meningococcal vaccination. The public-private partnerships for conducting research and development, and manufacturing of quality vaccines at an affordable price are also contributing positively in driving market growth. Awareness campaigning from government and non-profit organizations and obligatory immunization for individuals heading toMecca (for Hajj pilgrimage) and the South African meningitis belt will also contribute to growth of this market. High cost of few but vital vaccines, such as Bexsero, and need for efficient cold chain logistics to maintain safety and efficacy of the vaccine are expected to be some of the major factors posing a challenge to the adequate uptake of these vaccines.

The key players dominating in the global meningococcal vaccines include Sanofi Pasteur (the vaccine division of Sanofi SA), Novartis International AG and GSK plc. These players account for more than 80% of the meningococcal vaccines market. Players such as Serum Institute of India Ltd., JN International Medical Corporation, Biomed Pvt. Ltd., Nuron Biotech and Baxter account for the remaining market share.

 

Browse Meningococcal Vaccines Market Report With Full TOC http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html

Related & Recently Published Reports by Transparency Market Research:

 
Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading